Focus: Cancer Center Featured Story 2

Filters close
Released: 17-Jun-2021 1:50 PM EDT
Red meat consumption may promote DNA damage-assoc. mutation in colorectal cancer patients
American Association for Cancer Research (AACR)

Genetic mutations indicative of DNA damage were associated with high red meat consumption and increased cancer-related mortality in patients with colorectal cancer.

Newswise: Study Shows Immunotherapy Drug Combination Improves Response in HER2-Negative Breast Cancer Including a Subset of Estrogen Receptor Positive Cancers
Released: 17-Jun-2021 1:15 PM EDT
Study Shows Immunotherapy Drug Combination Improves Response in HER2-Negative Breast Cancer Including a Subset of Estrogen Receptor Positive Cancers
Yale Cancer Center

In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen receptor positive cancers.

Newswise: Engineered NK cells can eliminate glioblastoma stem cells
16-Jun-2021 5:35 PM EDT
Engineered NK cells can eliminate glioblastoma stem cells
University of Texas M. D. Anderson Cancer Center

Preclinical research finds that glioblastoma stem cells can be targeted by NK cells, but they are able to evade immune attack by releasing TFG-β. Deleting the TFG-β receptor in NK cells renders them resistant to this and restores their anti-tumor activity.

Released: 17-Jun-2021 11:35 AM EDT
Moffitt Researchers Develop Non-invasive Approach to Measure Biomarker Levels, Predict Outcomes in Lung Cancer Patients
Moffitt Cancer Center

In a new article published in the Journal for ImmunoTherapy of Cancer, Moffitt Cancer Center researchers show that PET/CT images can be used to measure levels of the PD-L1 biomarker of non-small cell lung cancer (NSCLC) patients in a non-invasive manner and, in turn, predict a patient’s response to therapy.

15-Jun-2021 11:40 AM EDT
Antibiotic Novobiocin Found to Kill Tumor Cells with DNA-Repair Glitch
Dana-Farber Cancer Institute

An antibiotic developed in the 1950s and largely supplanted by newer drugs, effectively targets and kills cancer cells with a common genetic defect, laboratory research by Dana-Farber Cancer Institute scientists shows. The findings have spurred investigators to open a clinical trial of the drug, novobiocin, for patients whose tumors carry the abnormality.

Newswise: UC Davis Clinical Translational Science Center Awarded 5-year Grant Renewal From NIH
Released: 17-Jun-2021 8:00 AM EDT
UC Davis Clinical Translational Science Center Awarded 5-year Grant Renewal From NIH
UC Davis Health

The UC Davis Clinical Translational Science Center (CTSC) received notice of its third National Institutes of Health (NIH) award renewal. The 5-year award, almost $33 million, provides critical funding to continue CTSC’s essential services for the UC Davis research community.

Released: 16-Jun-2021 11:40 AM EDT
MD Anderson Research Highlights for June 16, 2021
University of Texas M. D. Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a new combination therapy for acute myeloid leukemia (AML), a greater understanding of persistent conditions after AML remission, the discovery of a universal biomarker for exosomes, the identification of a tumor suppressor gene in hepatocellular carcinoma (HCC) and characterization of a new target to treat Clostridioides difficile (C. difficile) infections.

Released: 15-Jun-2021 1:55 PM EDT
NCCN Policy Summit Explores How COVID-19 Pandemic Can Lead to Improvements in Cancer Care
National Comprehensive Cancer Network® (NCCN®)

NCCN Policy Summit examines the impact of the past year on oncology policy in the U.S., such as resuming recommended screening and clinical trials, applying health innovations from the COVID-19 pandemic to cancer treatment, and addressing systemic inequalities that lead to disparities in outcomes.

Newswise: Yale Cancer Center Study Reveals New Pathway for Brain Tumor Therapy
Released: 15-Jun-2021 12:05 PM EDT
Yale Cancer Center Study Reveals New Pathway for Brain Tumor Therapy
Yale Cancer Center

In a new study led by Yale Cancer Center, researchers show the nucleoside transporter ENT2 may offer an unexpected path to circumventing the blood-brain barrier (BBB) and enabling targeted treatment of brain tumors with a cell-penetrating anti-DNA autoantibody.

Newswise: Ludwig Cancer Research Study Shows How Certain Macrophages Dampen Anti-Tumor Immunity
10-Jun-2021 11:05 AM EDT
Ludwig Cancer Research Study Shows How Certain Macrophages Dampen Anti-Tumor Immunity
Ludwig Cancer Research

A Ludwig Cancer Research study adds to growing evidence that immune cells known as macrophages inhabiting the body cavities that house our vital organs can aid tumor growth by distracting the immune system’s cancer-killing CD8+ T cells. Reported in the current issue of Cancer Cell and led by Ludwig investigators Taha Merghoub and Jedd Wolchok at Memorial Sloan Kettering (MSK) and Charles Rudin of MSK, the study shows that cavity-resident macrophages express high levels of Tim-4, a receptor for phosphatidylserine (PS), a molecule that they surprisingly found on the surface of highly activated, cytotoxic and proliferative CD8+ T-cells.

9-Jun-2021 11:05 AM EDT
Combination targeted therapy provides durable remission for patients with chronic lymphocytic leukemia
University of Texas M. D. Anderson Cancer Center

A combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia (CLL), according to researchers at The University of Texas MD Anderson Cancer Center. Findings from the single-institution Phase II study were published today in JAMA Oncology and provide the longest follow-up data on patients treated with this drug regimen.

Released: 9-Jun-2021 6:30 PM EDT
Targeted Therapy Pralsetinib Safely and Effectively Treats Lung and Thyroid Cancers with RET Alterations
University of Texas M. D. Anderson Cancer Center

Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was safe and effective in treating patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) and RET-altered thyroid cancer.

Released: 9-Jun-2021 3:05 PM EDT
New Insights on Sarcomatoid Kidney Cancer: Roswell Park Reports Clear Benefit from Checkpoint Inhibitors
Roswell Park Comprehensive Cancer Center

New collaborative research shows that treatment with immune checkpoint inhibitors (ICIs) has led to a significant improvement in survival and response rates among patients with a particularly aggressive type of kidney cancer: advanced sarcomatoid renal cell carcinoma. The study, which was led by a team from Roswell Park Comprehensive Cancer Center and involved contributors from six centers, is detailed in a presentation at the American Society of Clinical Oncology 2021 virtual annual meeting (abstract 4568).

Released: 9-Jun-2021 1:05 PM EDT
Breast Cancer Study: African Americans Not Experiencing Complete Response to Extent Other Groups Are
Roswell Park Comprehensive Cancer Center

Researchers at Roswell Park Comprehensive Cancer Center led the largest study to date to suggest an improving trend in pathologic complete response rates over time for U.S. cancer patients of various races. The team's findings, documented in a poster presentation at the 2021 American Society of Clinical Oncology virtual annual meeting (abstract 575), show that African Americans are more likely than patients from any other group to have remaining disease following breast cancer treatment.

Released: 9-Jun-2021 12:10 PM EDT
Biomarker Uncovered by Roswell Park Team Identifies NET Patients Likely to Have Blood Side Effects from PRRT
Roswell Park Comprehensive Cancer Center

New work from a team at Roswell Park Comprehensive Cancer Center will help guide the care of patients with neuroendocrine tumors, or NETs. In a poster presentation at the American Society of Clinical Oncology (ASCO) virtual Annual Meeting 2021, Abhay Singh, MD, MPH, and colleagues outline their discovery of a potential biomarker to predict which patients are likely to experience blood toxicity side effects from a new targeted radiation treatment, peptide receptor radionuclide therapy (PRRT).

Newswise: Ludwig Cancer Research Study Employs Novel Drug Screen to Identify a Potential Individualized Triple-Negative Breast Cancer Therapy
8-Jun-2021 2:00 PM EDT
Ludwig Cancer Research Study Employs Novel Drug Screen to Identify a Potential Individualized Triple-Negative Breast Cancer Therapy
Ludwig Cancer Research

A study conducted by researchers at the Ludwig Center at Harvard has demonstrated how a drug screening method known as dynamic BH3 profiling can be used to quickly identify potentially effective combinations of existing drugs for personalized cancer therapy.

Newswise: First in the World! Chulalongkorn Hospital Successfully Treats a Breast Cancer Patient with Immunotherapy
Released: 8-Jun-2021 8:55 AM EDT
First in the World! Chulalongkorn Hospital Successfully Treats a Breast Cancer Patient with Immunotherapy
Chulalongkorn University

Queen Sirikit Center for Breast Cancer, King Chulalongkorn Memorial Hospital, Thai Red Cross Society (Chulalongkorn Hospital) has become the world’s first institution to have successfully used immunotherapy to treat a breast cancer patient who is now in complete remission with minimal side effects and uplifted quality of life.

Newswise: Yale Cancer Center Study Shows Novel Test Can Detect New and Recurrent Bladder Cancer
Released: 7-Jun-2021 6:40 PM EDT
Yale Cancer Center Study Shows Novel Test Can Detect New and Recurrent Bladder Cancer
Yale Cancer Center

A study led by researchers at Yale Cancer Center, Stony Brook University and KDx Diagnostics, Inc., examined a revolutionary new urine screening test that utilizes a novel Keratin 17 (K17) cancer biomarker, and revealed the test can detect the presence of new bladder cancer in patients with hematuria, or blood in the urine.

Released: 7-Jun-2021 6:05 AM EDT
To Train a Scientist
University of New Mexico Comprehensive Cancer Center

The University of New Mexico Comprehensive Cancer Center is using a grant from the American Cancer Society to introduce more underrepresented minority undergraduate students to cancer research

Newswise: 20201117_zsiros-055.jpg
4-Jun-2021 9:00 PM EDT
Roswell Park Team Demonstrates Safe Approach for Dramatically Reducing Use of Opioids Following Surgery
Roswell Park Comprehensive Cancer Center

A pain-management protocol designed by Emese Zsiros, MD, PhD, FACOG, to be reported at the American Society of Clinical Oncology 2021 annual meeting, resulted in a 45% decrease in opioids prescribed to patients undergoing surgery, without significant effect on recovery or satisfaction.

Newswise: Research From Roswell Park and Kaiser Permanente Supports Vitamin D Supplementation for Breast Cancer Patients
Released: 4-Jun-2021 5:10 PM EDT
Research From Roswell Park and Kaiser Permanente Supports Vitamin D Supplementation for Breast Cancer Patients
Roswell Park Comprehensive Cancer Center

The Roswell Park Comprehensive Cancer Center/Kaiser Permanente Northern California team behind a new study to be highlighted at the ASCO 2021 virtual annual meeting has found that sufficient vitamin D levels at the time of diagnosis are associated with improved outcomes among people with breast cancer.

Newswise: Newly approved targeted therapy sotorasib prolongs survival in KRAS G12C-mutated lung cancer
4-Jun-2021 10:10 AM EDT
Newly approved targeted therapy sotorasib prolongs survival in KRAS G12C-mutated lung cancer
University of Texas M. D. Anderson Cancer Center

Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved 12.5 months median overall survival in previously treated patients with KRAS G12C-mutated non-small cell lung cancer, according to researchers from The University of Texas MD Anderson Cancer Center.

Newswise: Most Californians unaware of law to prevent gun violence but would support using it
Released: 4-Jun-2021 11:00 AM EDT
Most Californians unaware of law to prevent gun violence but would support using it
UC Davis Health

A new study shows that two-thirds of Californians don’t know about a law designed to prevent a person at risk of hurting themselves or others from possessing or purchasing firearms or ammunition. More than 80% of survey participants were supportive once they read about this law.

Released: 3-Jun-2021 5:10 PM EDT
Roswell Park Researchers Gear Up for ASCO 2021 Annual Meeting
Roswell Park Comprehensive Cancer Center

At the American Society of Clinical Oncology 2021 virtual Annual Meeting, Roswell Park teams will share data and insights on topics ranging from reducing use of opioids to an analysis of trends in response to cancer treatment among patients of different races.

3-Jun-2021 1:00 PM EDT
ASCO 2021: PSMA-Targeted Radioligand Therapy Improves Survival in Metastatic Prostate Cancer
Memorial Sloan Kettering Cancer Center

New data from researchers at Memorial Sloan Kettering Cancer Center (MSK) featured in the 2021 ASCO Annual Meeting press program highlights a promising new treatment option for individuals previously treated for metastatic castration-resistant prostate cancer (mCRPC).

3-Jun-2021 4:45 PM EDT
Immunotherapy drug delays recurrence in kidney cancer patients
Dana-Farber Cancer Institute

Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of a phase 3 clinical trial of adjuvant immunotherapy in this patient population.

Newswise: Immunotherapy after Bladder Cancer Surgery May Reduce Recurrence, Study Shows
Released: 3-Jun-2021 4:30 PM EDT
Immunotherapy after Bladder Cancer Surgery May Reduce Recurrence, Study Shows
Memorial Sloan Kettering Cancer Center

New research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD, and colleagues found that patients who received nivolumab (Opdivo®) after bladder cancer surgery reduced their overall risk for high-grade bladder cancer recurrence. This research was published today in the New England Journal of Medicine.

Released: 3-Jun-2021 2:10 PM EDT
Analyzing the Tumor Microenvironment at the Single Cell Level Sheds Light on Metastatic Melanoma Outcomes, Moffitt Study Shows
Moffitt Cancer Center

In a new article published in Clinical Cancer Research, Moffitt Cancer Center researchers reveal how different therapies impact the surrounding immune environment of metastatic melanoma tumors according to location and identify a rare population of immune cells that is associated with improved overall survival.

Released: 3-Jun-2021 12:00 PM EDT
Researchers discover potential new approach to treating psoriatic joint inflammation
UC Davis Health

An international team of researchers, led by UC Davis Health, developed a new therapeutic approach to treating psoriatic arthritis, a chronic inflammatory disease affecting the joints.

Released: 2-Jun-2021 5:30 PM EDT
Tip Sheet: Massive unmet needs in COVID-19 treatment, osteoporosis drugs for breast cancer, new bladder cancer target — and AIDS at 40
Fred Hutchinson Cancer Research Center

SEATTLE — June 2, 2021 — Below are summaries of recent Fred Hutch research findings and other news. If you are covering news at the annual meeting of the American Society of Clinical Oncology (June 4-8), check out our ASCO page highlighting Fred Hutch presentations and feel free to reach out to our media team for help sourcing experts:

1-Jun-2021 9:00 AM EDT
New NCCN Employer Toolkit Enables Organizations to Help Workers with Cancer
National Comprehensive Cancer Network® (NCCN®)

Free resource from the National Comprehensive Cancer Network helps employers select health plans and provide services to improve employee outcomes and minimize disruptions from cancer diagnoses—now available at NCCN.org/employertoolkit

Newswise: Pride, Progress and Breaking down Barriers: LGBTQ+ Cancer Concerns
Released: 2-Jun-2021 8:05 AM EDT
Pride, Progress and Breaking down Barriers: LGBTQ+ Cancer Concerns
Rutgers Cancer Institute of New Jersey

A person with cancer who identifies as lesbian, gay, bisexual, transgender or non-binary may have unique concerns about communicating with their cancer care team, navigating the healthcare system and coping with their diagnosis. An expert from Rutgers Cancer Institute calls attention to the healthcare challenges and barriers faced by this community during Pride Month and explains how health care professionals are becoming better allies.

Newswise: Lerman Takes the Reins as AACI President
Released: 1-Jun-2021 12:00 PM EDT
Lerman Takes the Reins as AACI President
Association of American Cancer Institutes (AACI)

USC Norris Comprehensive Cancer Center Director Caryn Lerman, PhD, is the new president of the Association of American Cancer Institutes (AACI). She begins her two-year term early due to Karen E. Knudsen, MBA, PhD, stepping down to become the new CEO of the American Cancer Society.

Released: 1-Jun-2021 9:25 AM EDT
Moffitt Cancer Center Experts to Present New Clinical Research Data
Moffitt Cancer Center

Moffitt Cancer Center, a national leader in cancer care and research and the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, is presenting new data from dozens of clinical research studies at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, the world’s largest clinical cancer research meeting. Moffitt investigators will lead 25 abstract presentations, five education sessions, two cancer-based panels and two clinical science symposia. The virtual meeting is June 4-8.

Newswise: Identifying Potential Treatment for Triple Negative Breast Cancer
Released: 1-Jun-2021 8:05 AM EDT
Identifying Potential Treatment for Triple Negative Breast Cancer
Rutgers Cancer Institute of New Jersey

Researchers at Rutgers Cancer Institute of New Jersey and Rutgers New Jersey Medical School (NJMS) recently discovered a phage display-based approach to halt tumor growth that could be used to treat triple-negative breast cancer – considered the most aggressive type of breast cancer. The findings were published online in the scientific journal eLife.

Released: 27-May-2021 2:30 PM EDT
Survival benefits of immunotherapy combination persist for more than six years in patients with advanced melanoma
Dana-Farber Cancer Institute

In the longest follow-up results from a clinical trial of combination immunotherapy for metastatic melanoma, investigators report that nearly half the patients who received the drugs nivolumab and ipilimumab were alive a median of six and a half years after treatment.

Released: 26-May-2021 3:45 PM EDT
Head and neck cancer cells hijack nearby healthy tissue, promoting further invasion of cancer cells
University of Michigan

Up to half of patients with head and neck squamous cell carcinoma will experience tumor recurrence or new tumors—tumors that often spread and are difficult to treat.

Newswise: Glioblastoma study discovers protective role of metabolic enzyme, revealing a novel therapeutic target
25-May-2021 5:35 PM EDT
Glioblastoma study discovers protective role of metabolic enzyme, revealing a novel therapeutic target
University of Texas M. D. Anderson Cancer Center

MD Anderson researchers have discovered a new role for the metabolic enzyme, MCAD, in glioblastoma. The enzyme prevents toxic fatty acid accumulation, in addition to its normal role in energy production, and targeting MCAD led to irreversible damage and cell death specifically in cancer cells.

Released: 25-May-2021 7:00 PM EDT
Cancer Research Institute Celebrates Ninth Annual Cancer Immunotherapy Month™
Cancer Research Institute

Cancer Research Institute celebrates progress in cancer immunotherapy research, announces new initiatives aimed at addressing racial and ethnic disparities in cancer treatment and academic research, during ninth annual Cancer Immunotherapy Month this June.

Released: 24-May-2021 11:25 AM EDT
Kansas Must Plan to End Tobacco Sales
University of Kansas Cancer Center

The University of Kansas Cancer Center joins 148 organizations from around the world in this public health appeal

Newswise: NCCN Annual Award Honors Dr. Mary Daly for Key Contributions to Guidelines Program; 
Recognizes Meetings Department Director with Staff Award
Released: 24-May-2021 8:35 AM EDT
NCCN Annual Award Honors Dr. Mary Daly for Key Contributions to Guidelines Program; Recognizes Meetings Department Director with Staff Award
National Comprehensive Cancer Network® (NCCN®)

NCCN annual award recognizes Dr. Mary Daly for her pioneering role in the field of genetics and family history in assessing cancer risk, particularly for breast, ovarian, and pancreatic cancers.

Newswise: Top Cancer Centers Call for Urgent Action to Get Cancer-Preventing HPV Vaccination Back on Track
Released: 20-May-2021 2:05 PM EDT
Top Cancer Centers Call for Urgent Action to Get Cancer-Preventing HPV Vaccination Back on Track
Roswell Park Comprehensive Cancer Center

As part of a unanimous effort on the part of the nation’s 71 National Cancer Institute (NCI)-designated cancer centers, Roswell Park Comprehensive Cancer Center is urging the nation’s physicians, parents and young adults to get cancer-preventing human papillomavirus (HPV) vaccination back on track.

Released: 20-May-2021 12:25 PM EDT
The University of Kansas Cancer Center joins other top US cancer centers in urgent call to get HPV vaccination back on track
University of Kansas Cancer Center

The University of Kansas Cancer Center has partnered with 70 other National Cancer Institute (NCI)-designated cancer centers and partner organizations to issue a joint statement urging the nation’s physicians, parents and young adults to get the human papillomavirus (HPV) vaccination back on track.

Newswise: New AI-based tool can find rare cell populations in large single-cell datasets
19-May-2021 3:55 PM EDT
New AI-based tool can find rare cell populations in large single-cell datasets
University of Texas M. D. Anderson Cancer Center

MD Anderson researchers have developed a first-of-its-kind AI tool to identify rare groups of biologically important cells from the noise of large, complex single-cell datasets. The new tool, called SCMER, can help reserachers gain new insights across many applications.

Newswise: Combination Therapy Achieves High Rates of Response for Patients with Acute Lymphoblastic Leukemia
18-May-2021 5:00 PM EDT
Combination Therapy Achieves High Rates of Response for Patients with Acute Lymphoblastic Leukemia
University of Texas M. D. Anderson Cancer Center

A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), according to researchers at The University of Texas MD Anderson Cancer Center. The study may support a regimen to produce complete remission with front-line therapy, without the increased risks associated with systemic chemotherapy or a stem cell transplant.

19-May-2021 4:05 PM EDT
Immunotherapy combination shows benefit for patients with advanced melanoma, phase 3 trial shows
Dana-Farber Cancer Institute

A combination of two drugs that target different proteins on immune system T cells kept advanced melanoma in check significantly longer than one of the drugs alone in a phase 3 clinical trial involving 714 patients. Dana-Farber Cancer Institute investigators co-led the study.

19-May-2021 4:30 PM EDT
Dana-Farber researchers present key studies at ASCO annual meeting
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute researchers are presenting dozens of research studies at the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO). The studies will be presented during the virtual program on June 4-8, 2021. ASCO is the world’s largest clinical cancer research meeting, attracting more than 30,000 oncology professionals from around the world.

Newswise: Metabolic inhibitor IACS-6274 shows early antitumor effects in underserved patients with advanced cancers
19-May-2021 12:05 PM EDT
Metabolic inhibitor IACS-6274 shows early antitumor effects in underserved patients with advanced cancers
University of Texas M. D. Anderson Cancer Center

A metabolic inhibitor drug, IACS-6274, developed by MD Anderson's Therapeutics Discovery division, is well-tolerated and showed early signs of anti-tumor activity in a Phase I trial being presented at the 2021 ASCO Annual Meeting.

Newswise: Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Present 
Extensive, Wide-Ranging New Cancer Research Data at the 2021 ASCO Annual Meeting
19-May-2021 1:00 PM EDT
Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Present Extensive, Wide-Ranging New Cancer Research Data at the 2021 ASCO Annual Meeting
Rutgers Cancer Institute of New Jersey

Rutgers Cancer Institute of New Jersey, a leader in cutting-edge clinical trials and health outcomes analyses and a designated Comprehensive Cancer Center by the National Cancer Institute, together with RWJBarnabas Health, today announced that data from its cancer clinical research program will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held virtually from June 4-8.


Showing results

150 of 2421

close
1.65456